Creso Pharma (ASX:CPH) grows revenue and market presence in Q4, page-15

Anyone 'for' this stock is just the paid hypers/stock promoters left in this forum it looks like.

Nothing has changed, continued pay outs to Adam Blumanethal and I'm assuming the companies financial report hasn't changed in the last 2 years (not spending the time reading through it), meaning siphoning money into their own pockets and excessive expenses on basically fluff to cover up their payments to themselves - Nothing to see here, this should be sub 3c by end of the year where it (may) be fair value, or at least much fairer than now.